ImmunityBio (IBRX) Share-based Compensation (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Share-based Compensation of $16.4 million for Q1 2026, up 173.91% quarter-over-quarter from -$22.2 million in Q4 2025.
ImmunityBio (IBRX) Share-based Compensation (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Share-based Compensation for 13 consecutive years, with $16.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation changed N/A year-over-year to $16.4 million; the TTM figure through Mar 2026 stood at $22.3 million (up 107.16% YoY), while the FY2025 annual figure was $5.9 million, down 59.63% from the prior year.
- Share-based Compensation advanced to $16.4 million in Q1 2026 per IBRX's latest filing, from -$22.2 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $26.5 million in Q3 2025 and bottomed at -$22.2 million in Q4 2025.
- Historically, Share-based Compensation has averaged $3.0 million across 5 years, with a median of $2.7 million in 2024.
- On a YoY basis, Share-based Compensation climbed as much as 2824.19% in 2023 and fell as far as 69840.0% in 2023.
- ImmunityBio's Share-based Compensation stood at -$10.0 million in 2022, then jumped by 185.41% to $8.6 million in 2023, then grew by 16.16% to $10.0 million in 2024, then tumbled by 322.47% to -$22.2 million in 2025, then soared by 173.91% to $16.4 million in 2026.
- Business Quant data shows IBRX's Share-based Compensation at $16.4 million in Q1 2026, -$22.2 million in Q4 2025, and $26.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | 886,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 886,000.00 |
| Jun 30, 2026 | 886,000.00 |
| Mar 31, 2026 | 16.38 Mn |
| Mar 31, 2026 | 16.38 Mn |
| Dec 31, 2025 | -22.16 Mn |
| Dec 31, 2025 | -22.16 Mn |
| Sep 30, 2025 | 26.54 Mn |
| Sep 30, 2025 | 26.54 Mn |
| Jun 30, 2025 | 1.52 Mn |
| Jun 30, 2025 | 1.52 Mn |
| Dec 31, 2024 | 9.96 Mn |
| Dec 31, 2024 | 9.96 Mn |
| Sep 30, 2024 | 4.66 Mn |
| Sep 30, 2024 | 4.66 Mn |
| Jun 30, 2024 | -3.87 Mn |
| Jun 30, 2024 | -3.87 Mn |
| Mar 31, 2024 | 3.87 Mn |
| Mar 31, 2024 | 3.87 Mn |
| Dec 31, 2023 | 8.58 Mn |
| Dec 31, 2023 | 8.58 Mn |